Prolonged Cardiac ECG Patch Versus Conventional Holter For Detecting Atrial Fibrillation After Cerebral Ischemic Event

NCT ID: NCT05082467

Last Updated: 2025-05-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

320 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-12

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to compare the diagnostic yield of water-resistant, wireless 7-day cardiac ECG patch versus conventional 24-hour Holter recording in detecting paroxysmal atrial fibrillation in patients admitted with acute ischemic stroke or transient ischemic attack of undetermined etiology after completion of a standard clinical stroke workup.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a cohort study with a paired comparison between a cardiac ECG patch and conventional Holter system to detect atrial fibrillation in patients with acute ischemic stroke or transient ischemic attack of undetermined etiology. An estimated total of 320 adult patients will be enrolled in this study. Each eligible patient will receive simultaneously a conventional 24h Holter monitoring and a 7d cardiac ECG patch monitoring.

OBJECTIVES:

Primary objective:

To determine the diagnostic yield of a cardiac ECG patch compared to conventional Holter monitor for detecting occult paroxysmal atrial fibrillation (AF) within 24 hours in patients admitted with acute ischemic stroke or transient ischemic attack (TIA) of undetermined etiology after completion of a standard clinical stroke work-up.

Secondary objective(s):

* To determine efficacy of prolonged 7-day ambulatory ECG monitoring (using cardiac ECG patch) compared to conventional 24-hour ambulatory ECG monitoring (using conventional Holter) strategies in detecting paroxysmal AF.
* To determine if a strategy of a prolonged 7-day ambulatory ECG monitoring results in a change in clinical practice, i.e., more patients are anticoagulated.
* To assess the time to the first detection of AF within the first 7 days of monitoring.

Exploratory objective(s):

* To identify predictors of occult AF based on clinical, neuroimaging, echocardiography, and ECG features.
* To assess feasibility and cost-effectiveness of 7-day cardiac ECG patch monitoring for detecting occult paroxysmal AF.

SCREENING:

* Written informed consent obtained from patient or guardian
* Inclusion/Exclusion criteria.
* Social demographics, Risk factors, Comorbidities, Admission Brain CT/MRI,Stroke status including date and time of index event, date and time of admission, admission modified Rankin scale/NIHSS Score \[Data extracted from patient records\].
* 12-lead ECG, Transthoracic Echocardiogram

Eligible patients will be enrolled in the study and proceed with a baseline assessment.

BASELINE ASSESSMENT:

* Concomitant medication, Oxfordshire classification of stroke and CHA2DS2VAS Score \[Data extracted from patient records\].
* Anthropometric measurements and vital signs assessments
* 24h Holter and 7d Cardiac ECG patch monitoring

FOLLOW UP VISITS:

Follow-up visits will occur at 3 months and 1 year for the efficacy and outcomes for the duration of the study. There will be a total of 2 visits.The investigator/study team will perform the following procedures at each visit where applicable:

* Clinical examination (NIHSS Score assessment)
* Review concomitant medications
* AE/SAE assessment and monitoring
* Outcomes assessment
* Health outcome interview with EQ-5D Questionnaire
* TOAST Classification (at 1 year follow up visit)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥18 years.
2. Diagnosis of acute ischemic stroke or transient ischemic attack (TIA) (WHO definition) of undetermined etiology made by neurologist within 7 days after the index event. The event must be either:

* an ischemic stroke confirmed by neuroimaging; or
* a TIA, defined as involving a focal unilateral motor deficit, speech/language deficit or hemianopia, with symptom duration \<24 hours (note: amaurosis fugax/ transient monocular blindness, pure sensory spells, isolated vertigo spells, etc. do not qualify for enrolment given the potential for misdiagnosis of such events).
3. No AF detected in baseline 12-lead ECG on admission.
4. The following diagnostic test have already been completed as part of clinical routine post-stroke/TIA:

* Brain imaging with CT or MRI,
* Transthoracic echocardiography to congenital heart disease and endocarditis.

Exclusion Criteria

1. Stroke of unknown time of symptom onset.
2. Modified Rankin Scale ≥5 on index admission.
3. Previous documented history of primary intracerebral bleeding.
4. Previous documented history of AF or atrial flutter (a remote history of transient AF during perioperative period is not exclusionary).
5. Skin allergies, conditions, or sensitivities to cardiac patch.
6. Exclusively retinal stroke or retinal TIA event.
7. Pre-existing indication for anticoagulation (eg. History of mechanical heart valve replacement, deep vein thrombosis).
8. Pre-existing contraindication for permanent anticoagulation (eg. hypocoagulable state).
9. Echocardiographic findings of congenital heart disease and endocarditis.
10. Indicated for pacemaker, implantable cardiac defibrillator (ICD), CRT device, or an implantable hemodynamic monitoring system.
11. Intravenous drug users (IVDUs).
12. Life expectancy \< 1 year for reasons other than stroke (eg. Metastatic cancer disease).
13. Concomitant participation in other clinical trials involving investigational medications.
14. Pregnancy.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sarawak Heart Centre

OTHER

Sponsor Role collaborator

Ministry of Health, Malaysia

OTHER_GOV

Sponsor Role collaborator

Sarawak General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Diana Hui Ping Foo

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Diana Hui Ping Foo, MD

Role: PRINCIPAL_INVESTIGATOR

Sarawak General Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sarawak General Hospital

Kuching, Sarawak, Malaysia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Malaysia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NMRR-19-3798-52441

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.